The estimated Net Worth of Riccardo Perfetti is at least $9.77 Million dollars as of 22 August 2024. Riccardo Perfetti owns over 22,681 units of Applied Therapeutics stock worth over $5,141,504 and over the last 5 years he sold APLT stock worth over $1,267,808. In addition, he makes $3,357,320 as Chief Medical Officer at Applied Therapeutics.
Riccardo has made over 27 trades of the Applied Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 22,681 units of APLT stock worth $132,230 on 22 August 2024.
The largest trade he's ever made was selling 110,804 units of Applied Therapeutics stock on 14 March 2024 worth over $597,234. On average, Riccardo trades about 10,238 units every 40 days since 2019. As of 22 August 2024 he still owns at least 986,853 units of Applied Therapeutics stock.
You can see the complete history of Riccardo Perfetti stock trades at the bottom of the page.
Dr. Riccardo Perfetti M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Perfetti served as a Senior Medical Officer, Vice President and Head of Global Medical Affairs, Diabetes and Cardiovascular Business Unit at Sanofi S.A., a publicly traded pharmaceutical company from October 2007 to September 2018. Prior to joining Sanofi, Dr. Perfetti served in various roles at Amgen Inc., a publicly traded biopharmaceutical company, including as a Director and Global Development Leader in diabetes, obesity, metabolism and endocrinology from December 2004 to August 2007. Dr. Perfetti was previously an associate professor of medicine at University of California in Los Angeles and a professor of medicine at the National Institutes of Health, or NIH. Dr. Perfetti practiced as an endocrinologist at Cedars-Sinai Medical Center and also served as Director of the Diabetes Research Laboratory and Director of the Outpatient Diabetes Program. Dr. Perfetti received his M.D. and Ph.D. in Endocrinology from University La Sapienza in Rome, Italy and received post-graduate training in endocrinology and molecular biology at NIH.
As the Chief Medical Officer of Applied Therapeutics, the total compensation of Riccardo Perfetti at Applied Therapeutics is $3,357,320. There are 1 executives at Applied Therapeutics getting paid more, with shoshana Shendelman having the highest compensation of $11,590,000.
Riccardo Perfetti is 60, he's been the Chief Medical Officer of Applied Therapeutics since 2018. There are 5 older and 6 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
Riccardo's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Over the last 5 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus, and Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: